MANGOCEUTICALS INC

Effective on October 16, 2024, at 12:01 a.m. Eastern Time, we affected a 1-for-15 reverse stock split of our then outstanding common stock, with any fractional shares rounded up to the nearest whole share (the “Reverse Stock Split”).

In connection with the Reverse Stock Split discussed above, all outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of common stock were adjusted, as required by the terms of each security. The number of shares available to be awarded under the Company’s equity incentive plans were also appropriately adjusted. Following the Reverse Stock Split, the par value of the common stock remained unchanged at $0.0001 par value per share. The Reverse Stock Split did not change the authorized number of shares of common stock or preferred stock.

The effects of the Reverse Stock Split have been retroactively reflected throughout this proxy statement.